1. Onconic Therapeutics IR: What to Expect

Scheduled for 9:00 AM on August 27, 2025, the IR session will include a presentation on Onconic’s business performance and current status, followed by a Q&A session. Detailed information on the sales growth of Jacubov and the clinical development progress of Nesuparib are expected to be key highlights.

2. Why Pay Attention?

Onconic Therapeutics is experiencing consistent growth driven by the market expansion of Jacubov and the potential of Nesuparib. This IR is a critical opportunity for the company to clearly communicate its growth story to investors and potentially re-evaluate its corporate value.

3. What Should Investors Do?

  • Verify Jacubov’s Continued Growth: Focus on sales trends since launch and the company’s future growth strategy.
  • Monitor Nesuparib’s Clinical Progress: Check for updates on clinical trial results, timelines, and potential licensing opportunities.
  • Assess Financial Health and Investment Plans: Evaluate the potential for stable growth based on the company’s strong financial position.
  • Analyze the Competitive Landscape: Understand the competitive dynamics in the P-CAB and anti-cancer drug markets, and Onconic’s strategies to address them.

4. Investor Action Plan

Carefully analyze the information presented during the IR and make investment decisions based on the company’s future growth potential. It’s crucial to maintain a long-term perspective and avoid being swayed by short-term stock price fluctuations.